Your session is about to expire
← Back to Search
Onvansertib 20 mg + Standard of Care for Colorectal Cancer
Study Summary
This trial aims to determine the most effective dose of onvansertib and evaluate its safety and effectiveness when combined with certain chemotherapy regimens in patients with a specific type of colorectal cancer that has
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the combination of Onvansertib 30 mg with Standard of Care been granted approval by the FDA?
"According to our assessment at Power, the safety rating for Onvansertib 30 mg + Standard of Care is a 2 on a scale from 1 to 3. This score corresponds with being in Phase 2 of the trial and indicates some existing safety data without evidence supporting effectiveness."
Are there any available vacancies for potential participants in this research study?
"Per clinicaltrials.gov, recruitment for this trial is currently closed. The trial was first listed on 11/16/2023 and last updated on 10/24/2023. Despite this particular study no longer accepting patients, there are a total of 954 other trials actively seeking participants at present."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger